Ordering Recommendation

Aids in management of patients with bladder cancer patients in conjunction with cystoscopy. Qualitative assay detects bladder tumor-associated antigen in urine of patients diagnosed with bladder cancer.

Mnemonic

BT REQUEST

Methodology

Qualitative Immunoassay

Performed

Mon-Fri

Reported

1-5 days

New York DOH Approval Status

Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Specimen Required

Patient Preparation
Collect

Voided urine or urine from a catheterized patient.

Specimen Preparation

Transfer 2 mL urine to an ARUP Standard Transport Tube.

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Do not use paper or foam cups for urine specimen collection or storage.

Remarks
Stability

Ambient: 48 hours; Refrigerated: 1 week; Frozen: 6 months

Reference Interval

Positive: Bladder tumor associated antigen detected.
Negative: Bladder tumor associated antigen not detected.

Interpretive Data

Results of this test should not be interpreted as absolute evidence of the presence or absence of bladder cancer. Any disease that would cause endogenous human complement factor H (hCFH) to leak into the bladder can cause a positive test result. Positive results have been associated with renal stones, nephritis, renal cancer (including upper tract TCC), urinary tract infections, cystitis, sexually transmitted diseases and recent trauma to the bladder or urinary tract. This test should not be used as a screening test for individuals without biopsy-confirmed bladder cancer. The result from the BTA stat test should be used only in conjunction with information available from the clinical evaluation of the patient and other diagnostic procedures.

Compliance Category

FDA

Note

Hotline History

N/A

CPT Codes

86294

Components

Component Test Code* Component Chart Name LOINC
2006604 Clinical History 22636-5
8100523 Bladder Tumor Antigen Specimen Source 66746-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Bladder Cancer
  • Bladder Tumor
  • Bladder Tumor Antigen
  • BTA
  • Cytology
  • Urinary Tract Cancer
  • Urothelial Carcinoma
Bladder Tumor Associated Antigen